Journal of Clinical Oncology
Articles in this Issue
Analysis of a pre-screening platform for clinical trials in patients with prostate cancer.
e17103 Background: The clinical development process is often delayed by slow patient enrollment. Currently, <5% of oncology patients participate in cli...
Dabrafenib and trametinib in the treatment of BRAF-mutated anaplastic thyroid cancers (ATC).
6093 Background: ATCs are rare, aggressive tumors with poor median overall survival (OS). Approximately 45% harbor BRAF V600 mutations driving tumor progr...
SOHO-01: Safety and efficacy of BAY 2927088 in patients with advanced <i>HER2</i> -mutant non-small cell lung cancer (NSCLC) who were pretreated but naïve to HER2-targeted therapy or had not received any treatment for advanced disease.
8504 Background: The potent, reversible HER2 tyrosine kinase inhibitor BAY 292708...
Association of IFITM3 with the efficacy of anti-PD1/PD-L1 therapy and regulation of immunosensitivity via MHC-I regulation in SCLC.
8105 Background: Majority of small cell lung cancer (SCLC) patients exhibit resistance to immune checkpoint inhibitors (ICIs), which is associated with th...
Single dose of neoadjuvant ipilimumab and nivolumab in resectable melanoma with CD8+ cell imaging: Interim results of the C-IT Neo trial.
9513 Background: Neoadjuvant (neoadj) immune checkpoint blockade (ICB) is standard of care for patients (pts) with resectable stage III/IV melanoma. A sin...
Real-world clinical outcome of sacituzumab govitecan (SG) in HER2-negative metastatic breast cancer.
e13047 Background: Sacituzumab govitecan (SG) is an anti-TROP2 antibody-drug conjugate (ADC) approved for the treatment of patients (pts) with HER2-negati...
Prevalence and predictors of brain metastases in metastatic prostate cancer.
e17046 Background: Brain metastases (BM) in metastatic prostate cancer (mPCa), although rare, are associated with a poor prognosis. Accurate predictors of...
Impact of time to neoadjuvant treatment initiation (TTI) for resectable non-small cell lung cancer (NSCLC) on clinical outcomes.
8069 Background: There has been significant progress in the management of resectable NSCLC, now utilizing biomarker selected criteria. However, in the era...
Correlation between the efficacy of anti-HER-2 targeted therapy and ctDNA status: A meta-analysis.
e13014 Background: Circulating tumor DNA (ctDNA) is a promising biomarker for cancer prognosis and therapeutic monitoring. While HER2-targeted therapies i...
First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial phase 1 results.
7505 Background: Bispecific antibodies (BsAbs) have begun to transform outcomes in MM. Emerging data suggest that targeting two MM antigens with T-cell re...
Social worker–driven distress screening among gynecologic oncology patients.
e23153 Background: While all cancer centers are required to screen for distress, there is a lack of standardization regarding the screening process....
Characteristics and predictors of chronic immune-related adverse events (irAEs) following anti-PD-1 (PD1) treatment for melanoma.
9528 Background: Adjuvant PD1 treatment improves clinical outcomes in high-risk resected melanoma. We have shown that adjuvant PD1 can lead to irAEs that...
Exploring the role of progastricsin/pepsinogen-c (PGC) in gastric carcinogenesis: A South Asian outlook.
e16024 Background: Progastricsin/Pepsinogen C (PGC) is an endo-protease expressed by gastric fundic cells, glandular cells, chief cells as well as by extr...
Total metabolic tumor volume for predicting cytokine release syndrome and treatment response in patients receiving bispecific antibodies for B-cell lymphoma.
7059 Background: CD20xCD3 bispecific antibodies (BsAb) show high response rates with manageable cytokine release syndrome (CRS) in B-cell non-Hodgkin lymp...
Rechallenge with epidermal growth factor receptor inhibitors for metastatic colorectal cancer: A systematic review and meta-analysis.
e15609 Background: Clonal evolution is a mechanism of treatment resistance against epidermal growth factor receptor inhibitors (EGFRi) in metastatic color...
Results of an artificial intelligence–based tool to predict financial toxicity early to facilitate early referral to hospital social workers.
e13681 Background: Financial toxicity (FT) in cancer care leads to reduced treatment adherence, quality of life, and increased mortality. The Atlanta Canc...
Efficacy and omics-based insights of TROP2 ADC in non–small cell lung cancer with or without actionable genomic alterations (AGAs).
8637 Background: TROP2 antibody–drug conjugate (ADC) has emerged as a promising strategy for advanced non-small cell lung cancer (NSCLC). A trend of enhan...
Clonal hematopoiesis (CH) in participants with metastatic castration-resistant prostate cancer (mCRPC) receiving <sup>177</sup> Lu-PSMA-617 or cabazitaxel: An exploratory post-hoc analysis of a randomized phase II trial (TheraP; ANZUP 1603).
5020 Background: The prostate-specific membrane antigen (PSMA)-targeted radioligand [¹⁷⁷Lu]Lu-PSMA-617 ( 177 Lu-PSMA-617) is an ef...
Efficacy and safety of HTMC0435 combination with temozolomide in relapsed extensive-stage small-cell lung cancer (ES-SCLC): A phase Ib/II study.
8097 Background: Treatment options for ES-SCLC in second-line setting are limited. HTMC0435, an oral PARP inhibitor, significantly reduced the ability of...
Evolving beyond the "unknown primary": Investigating histopathology after diagnostic transoral robotic surgery for microscopic HPV-associated oropharyngeal carcinoma.
6092 Background: Squamous cell carcinoma metastatic to the head and neck arising from an unknown primary tumor (hnSCCUP) is a common presentation for HPV-...
The number of lymph node dissections related to survival of patients with locally advanced esophageal squamous cell carcinoma after neoadjuvant therapy: A single-center study.
e16009 Background: The number of lymph node dissection (LND) in locally advanced esophageal squamous cell carcinoma (ESCC) after neoadjuvant therapy remai...
Racial and ethnic disparities in gastric cancer trends: A retrospective analysis of tumor location and incidence patterns (2009–2022).
e16127 Background: Gastric cancer is a globally prevalent malignancy, particularly in Eastern Asia, Eastern Europe, and South America, with lower incidenc...
A phase I study of asciminib in combination with dasatinib, prednisone, and blinatumomab for Ph-positive acute leukemia in adults.
6509 Background: Treatment of Ph+ acute lymphoblastic leukemia (ALL) requires potent BCR:ABL1 inhibition. Acquired resistance to the ATP-competitive ABL1...
The Selfie study: Cervical precancer detection using novel human papillomavirus biomarkers.
10533 Background: Human papillomavirus (HPV) causes the majority of cervical cancers worldwide. Dual stain cytology can detect HPV oncogenic activity thro...
Fruquintinib in combination with camrelizumab and paclitaxel liposome and nedaplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II study.
4042 Background: Previous studies have indicated a synergistic effect of fruquintinib in combination with chemotherapy or immunotherapy. Therefore, we con...